Increased shunt through the patent ductus arteriosus after surfactant replacement therapy
References (19)
- et al.
Artificial surfactant therapy in hyaline membrane disease
Lancet
(1980) - et al.
Dry artificial lung surfactant and its effect on very premature babies
Lancet
(1981) - et al.
Blood flow measurements with radionuclide labeled particles
Prog Cardiovasc Dis
(1977) - et al.
Developmental response to indomethacin: A comparison of isometric tension with PGE2 formation in the lamb ductus arteriosus
Prostaglandins
(1979) - et al.
Circulating prostaglandin E2 concentrations and patent ductus arteriosus in fetal and neonatal lambs
J Pediatr
(1980) - et al.
Effect of gestational age on pulmonary metabolism of prostaglandin E
Prostaglandins
(1981) - et al.
Microaerosol administration of synthetic dipalmitoyl lecithin in the respiratory distress syndrome
Can Med Assoc J
(1964) - et al.
Neonatal pulmonary ischemia. I. Clinical and physiological studies
Pediatrics
(1967) - et al.
Lung expansion in the premature rabbit fetus after tracheal deposition of surfactant
Pediatrics
(1972)
Cited by (95)
Surfactant and neonatal hemodynamics during the postnatal transition
2023, Seminars in Fetal and Neonatal MedicinePatent Ductus Arteriosus in the Preterm Infant
2023, Avery's Diseases of the NewbornPatent ductus arteriosus in preterm newborns: A tertiary hospital experience
2022, Revista Portuguesa de CardiologiaCitation Excerpt :Hyaline membrane disease not only increases the incidence of PDA in preterm infants but has also been associated with the efficacy of response to treatment of PDA with COX inhibitors.28 Additionally, surfactant administration causes a rapid decrease in pulmonary vascular resistance, contributing to increased left-to-right flow through the ductus arteriosus.29 However, in the present study we observed the presence of hyaline membrane disease in 90.1% of the sample, and surfactant was used in 84% of the preterm infants included in the study, making it difficult to assign an association for these variables.
Differential determinants of patent ductus arteriosus closure for prematurity of varying birth body weight: A Retrospective Cohort Study
2020, Pediatrics and NeonatologyCitation Excerpt :Clyman et al. proposed that increased circulating level of prostaglandin E associated with respiratory distress syndrome might contribute to the patency of ductus arteriosus.22 Increased ductal shunting after surfactant administration was reported.23 Our study result highlighted the independent role of surfactant on PDA closure.
Patent ductus arteriosus, its treatments, and the risks of pulmonary morbidity
2018, Seminars in PerinatologyCitation Excerpt :In preterm newborns, the decreased ability to maintain active precapillary pulmonary arterial tone7 allows the intravascular hydraulic pressure to distribute more of its force towards the downstream capillary fluid filtration sites.3 Anything that decreases precapillary tone (e.g., intrauterine growth restriction8 or surfactant administration9–11) can exacerbate the amount of left-to-right shunt, alter the distribution of pulmonary hydraulic pressures to downstream filtration sites, and lead to earlier pulmonary edema and pulmonary hemorrhage.8,11,12 Conversely, therapies that increase precapillary vasoconstriction (e.g., dopamine13) or precapillary resistance (e.g., red blood cell transfusions and increased blood viscosity14) can decrease the left-to-right PDA shunt and redistribute the pressure head upstream, away from the capillary bed.
Acute Effects and Long-Term Consequences
2018, The Newborn Lung: Neonatology Questions and Controversies, Third Edition
Supported by grants from the United States Public Health Service, Program Project Grants HL24056, HD12714, and HL 27356.